Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$4.60

0.27 (6.24%)

, EDIT

Editas Medicine

$14.51

0.45 (3.20%)

07:55
10/11/16
10/11
07:55
10/11/16
07:55

Jefferies to hold a summit

Gene Editing/Therapy Summit to be held in New York on October 11.

SGMO

Sangamo

$4.60

0.27 (6.24%)

EDIT

Editas Medicine

$14.51

0.45 (3.20%)

NTLA

Intellia Therapeutics

$14.44

-0.66 (-4.37%)

BOLD

Audentes Therapeutics

$18.34

-0.09 (-0.49%)

RGNX

Regenxbio

$17.82

1.63 (10.07%)

ABEO

Abeona Therapeutics

$6.86

0.07 (1.03%)

ONCE

Spark Therapeutics

$63.18

1.84 (3.00%)

  • 11

    Oct

  • 12

    Oct

  • 06

    Nov

SGMO Sangamo
$4.60

0.27 (6.24%)

08/04/16
JANY
08/04/16
DOWNGRADE
JANY
Neutral
Sangamo downgraded to Neutral from Buy at Janney Capital
09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.
12/17/15
12/17/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADP (ADP) initiated with a Neutral at Sterne Agee CRT... Accenture (ACN) initiated with a Buy at Sterne Agee CRT... Alliance Data (ADS) initiated with a Buy at Sterne Agee CRT... Axsome Therapies (AXSM) initiated with a Buy at Brean Capital... Blue Bird (BLBD) initiated with a Buy at Stifel... Burlington Stores (BURL) initiated with a Hold at BB&T... Chimerix (CMRX) initiated with a Buy at UBS... Cimarex Energy (XEC) initiated with a Buy at SunTrust... Clovis (CLVS) initiated with a Buy at Janney Capital... Cognizant (CTSH) initiated with a Neutral at Sterne Agee CRT... Container Store (TCS) initiated with a Neutral at Goldman... Cooper Companies (COO) initiated with a Neutral at Goldman... Corcept Therapeutics (CORT) initiated with a Buy at Janney Capital... Dave & Buster's (PLAY) initiated with an Outperform at BMO Capital... EPAM Systems (EPAM) initiated with a Buy at Sterne Agee CRT... FIS (FIS) initiated with a Neutral at Sterne Agee CRT... First Data (FDC) initiated with a Buy at Sterne Agee CRT... Fiserv (FISV) initiated with a Buy at Sterne Agee CRT... Frontline (FRO) initiated with a Buy at Seaport Global... Gener8 Maritime (GNRT) initiated with a Buy at Seaport Global... Genocea (GNCA) initiated with a Buy at UBS... Geron (GERN) initiated with a Buy at Janney Capital... Global Payments (GPN) initiated with a Buy at Sterne Agee CRT... Globant (GLOB) initiated with a Buy at Sterne Agee CRT... Harris (HRS) initiated with a Buy at Jefferies... Horizon Pharma (HZNP) initiated with a Buy at Goldman... Infosys (INFY) initiated with a Neutral at Sterne Agee CRT... Kate Spade (KATE) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with an Outperform at RBC Capital... MasterCard (MA) initiated with a Buy at Sterne Agee CRT... MicroVision (MVIS) initiated with a Buy at Rodman & Renshaw... Monro Muffler (MNRO) initiated with a Neutral at Goldman... Newfield Exploration (NFX) initiated with a Neutral at SunTrust... Orbital ATK (OA) initiated with a Buy at UBS... Paychex (PAYX) initiated with a Neutral at Sterne Agee CRT... Relypsa (RLYP) initiated with a Buy at H.C. Wainwright... Republic Services (RSG) initiated with an Overweight at JPMorgan... Ross Stores (ROST) initiated with a Buy at BB&T... Rubicon Project (RUBI) initiated with a Buy at Jefferies... Sangamo (SGMO) initiated with a Buy at Janney Capital... Skyworks (SWKS) initiated with a Buy at Chardan... TJX (TJX) initiated with a Buy at BB&T... TopBuild (BLD) initiated with an Overweight at Stephens... Unit Corp. (UNT) initiated with a Buy at SunTrust... Upland Software (UPLD) initiated with a Buy at Roth Capital... Virtusa (VRTU) initiated with a Neutral at Sterne Agee CRT... Visa (V) initiated with a Buy at Sterne Agee CRT... Waste Connections (WCN) initiated with an Overweight at JPMorgan... Waste Management (WM) initiated with a Neutral at JPMorgan... Williams-Sonoma (WSM) initiated with a Neutral at Guggenheim... Wipro (WIT) initiated with an Underperform at Sterne Agee CRT... vTv Therapeutics (VTVT) initiated with a Buy at Janney Capital.
03/07/16
JANY
03/07/16
NO CHANGE
Target $15
JANY
Buy
Sangamo data support expectations for IVPRP efficacy, says Janney Capital
Janney Capital analyst Roy Buchanan says that updated mouse data for Sangamo's in vivo protein replacement platform, or IVPRP, for treating MPS I and II continue to support expectations for efficacy and that the brain data is encouraging and adds additional support. The analyst notes, however, that he hasn't increased his probability of success for the program on this data, as much of it had been presented previously. Buchanan keeps a Buy rating and $15 fair value estimate on Sangamo shares.
EDIT Editas Medicine
$14.51

0.45 (3.20%)

08/10/16
JEFF
08/10/16
UPGRADE
Target $35
JEFF
Buy
Editas Medicine upgraded to Buy from Hold at Jefferies
Jefferies analyst Gena Wang upgraded Editas Medicine to Buy saying the recent pullback in the shares provides an opportunity to own the company's "transformative CRIPSR technology." The analyst keeps a $35 price target for the shares.
06/21/16
JANY
06/21/16
NO CHANGE
Target $48
JANY
Buy
Janney says Editas may be weak after UPenn scientists first to Cas9 RAC
Janney Capital analyst Roy Buchanan noted that members of the NIH's Recombinant DNA Advisory Committee, or RAC, were supportive of a phase 1 trial proposed by scientists at the University of Pennsylvania to test the use of CRISPR-Cas9 to create genetically altered immune cells to attack cancer. Buchanan noted shares of Editas Medicine may be impacted since the company will not be the first to the Cas9 RAC, as had been expected, but he noted this academic study will address a limited patient population, adding that "there is plenty of CAR-T/TCR space left to operate". The firm has a Buy rating and $48 fair value estimate on Editas shares.
06/02/16
JEFF
06/02/16
INITIATION
Target $35
JEFF
Hold
Editas Medicine initiated with a Hold at Jefferies
Jefferies analyst Gena Wang started Editas Medicine with a Hold rating and $35 price target.
02/29/16
02/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Brian Ossenbeck initiated a cautious outlook for the North American truckload sector, saying he believes "tepid" freight demand and a lack of a boost to consumer spending from low gas prices will lead the first contraction in realized revenue per loaded mile since 2007. Ossenteck initiated Werner (WERN) with an Overweight rating due to expectations that its diversification will drive a re-rating of its shares. The analyst set a Neutral rating on Swift Transport (SWFT) and Ryder (R), and an Underweight rating on Heartland Express (HTLD) and Knight Transportation (KNX). 2. Editas Medicine (EDIT) initiated with an Outperform at Cowen and JMP Securities, and a Neutral at JPMorgan. Cowen cited the company's "world-class expertise" in CRISPR, which will enable the development of a broad pipeline. JPMorgan analyst Cory Kasimov added that the company's CRISPR gene editing platform has the potential to be a game changer, but that it has "limited value-inflecting news" likely to come in 2016. 3. BeiGene (BGNE) initiated with an Outperform at Cowen citing the proof-of-concept data on each of four clinical candidates and expects to monetize those assets on the global stage. The company was also initiated with an Overweight and a Buy at Morgan Stanley and Goldman, respectively. 4. Nielsen (NLSN) initiated with a Buy at Jefferies by analyst Ryan Cary, who said the company is well positioned to benefit from demand for cross-platform viewership measurement and greenfield in emerging markets provides protection against macro headwinds. 5. Square (SQ) initiated with a Sector Weight at Pacific Crest by analyst Josh Beck, who said his optimism is balanced by the market's high expectations for execution, the uncertain regulatory environment for SMB lending, and software initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
NTLA Intellia Therapeutics
$14.44

-0.66 (-4.37%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
08/05/16
LEER
08/05/16
UPGRADE
Target $32
LEER
Outperform
Intellia Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink analyst Michael Schmidt upgraded Intellia Therapeutics to Outperform from Market Perform on valuation. The analyst believes the stock's current valuation represents an attractive entry point to own "one of the most exciting" technology platforms Biotech has to offer. Schmidt says Intellia Therapeutics is a leader in the development of CRISPR/Cas9-based genome editing therapeutics, and believes its platform has disruptive potential that could expand the potential of existing genome therapeutics. He has a $32 price target on the shares.
09/28/16
JANY
09/28/16
INITIATION
Target $29
JANY
Buy
Intellia Therapeutics initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Intellia Therapeutics with a Buy and a $29 fair value estimate.
08/05/16
JEFF
08/05/16
UPGRADE
Target $33
JEFF
Buy
Intellia Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies analyst Gena Wang upgraded Intellia Therapeutics to Buy following the company's Q2 results. The company has "transformative" gene-editing technology and has enough cash to support operation through 2020, Wang tells investors in a post-earnings research note. The analyst keeps a $33 price target for the shares.
BOLD Audentes Therapeutics
$18.34

-0.09 (-0.49%)

08/15/16
WEDB
08/15/16
INITIATION
Target $20
WEDB
Outperform
Audentes Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated Audentes Therapeutics with an Outperform and $20 price target saying its a compelling opportunity in AAV gene therapy of rare diseases.
08/15/16
COWN
08/15/16
INITIATION
COWN
Outperform
Audentes Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral started Audentes Therapeutics with an Outperform rating.
08/15/16
PIPR
08/15/16
INITIATION
Target $24
PIPR
Overweight
Audentes Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer started Audentes Therapeutics with an Overweight rating and $24 price target. The analyst views the company as well-positioned in the "rapidly evolving gene therapy landscape."
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
RGNX Regenxbio
$17.82

1.63 (10.07%)

10/20/15
CHDN
10/20/15
INITIATION
Target $33
CHDN
Buy
Regenxbio initiated with a Buy at Chardan
Target $33.
01/07/16
PIPR
01/07/16
NO CHANGE
Target $33
PIPR
Overweight
REGENXBIO pipeline expanding faster than expected, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said REGENXBIO's corporate updates released this morning show that its preclinical pipeline is expanding faster than he'd expected. The analyst continues to think that this year will include relevant newsflow for REGENXBIO as the company's vectors progress toward clinical development and keeps an Overweight rating on shares, but trimmed his price target to $33 from $36 to account for the company's guidance for a 2016 cash burn of $60M-$70M.
12/30/15
CHDN
12/30/15
NO CHANGE
Target $35
CHDN
Buy
REGENXBIO news a clear positive, says Chardan
Chardan analyst Gbolahan Amusa raised his price target for REGENXBIO shares to $35 from $33 after the FDA granted Rare Pediatric Disease Designation to RGX-111, the company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I. The designation could lead to a Rare Pediatric Disease Priority Review Voucher, which could be worth up to $8 per share, Amusa tells investors in a research note. The analyst keeps a Buy rating on the stock.
10/20/15
10/20/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with a Buy at Pivotal Research... AMC Networks (AMCX) initiated with a Market Perform at Cowen... Aduro Biotech (ADRO) initiated with an Outperform at Oppenheimer... CBS (CBS) initiated with a Buy at Pivotal Research... CDTi (CDTI) initiated with a Buy at Rodman & Renshaw... Callon Petroleum (CPE) initiated with a Buy at Canaccord... Cimarex Energy (XEC) initiated with a Hold at Canaccord... Cooper Tire (CTB) initiated with a Hold at Jefferies... Cubic (CUB) initiated with a Buy at BB&T... Diamond Offshore (DO) initiated with a Sell at Citi... Diamondback Energy (FANG) initiated with a Buy at Canaccord... Discovery (DISCA) initiated with a Buy at Pivotal Research... Disney (DIS) initiated with a Hold at Pivotal Research... Dorman Products (DORM) initiated with a Hold at Jefferies... Ensco (ESV) initiated with a Buy at Citi... First Data (FDC) initiated with a Positive at Susquehanna... InterOil (IOC) initiated with a Buy at Citi... Matador (MTDR) initiated with a Hold at Canaccord... Monro Muffler (MNRO) initiated with a Buy at Sterne Agee CRT... Noble Corp. (NE) initiated with a Neutral at Citi... Pacific Drilling (PACD) initiated with a Neutral at Citi... Parsley Energy (PE) initiated with a Buy at Canaccord... Pioneer Natural (PXD) initiated with a Buy at Canaccord... Pure Storage (PSTG) initiated with a Hold at Jefferies... Qorvo (QRVO) initiated with a Buy at Drexel Hamilton... RSP Permian (RSPP) initiated with a Hold at Canaccord... Regenxbio (RGNX) initiated with a Buy at Chardan... Reliance Steel (RS) initiated with a Buy at Deutsche Bank... Resonant (RESN) initiated with a Buy at Drexel Hamilton... Ring Energy (REI) initiated with a Buy at Canaccord... Rock Creek Pharmaceuticals (RCPI) initiated with a Buy at Maxim... Rowan Companies (RDC) initiated with a Neutral at Citi... Shire (SHPG) initiated with a Buy at BTIG... Skyworks (SWKS) initiated with a Buy at Drexel Hamilton... Snap-On (SNA) initiated with a Hold at Jefferies... Standard Motor (SMP) initiated with a Buy at Jefferies... Time Warner (TWX) initiated with a Buy at Pivotal Research... TowerJazz (TSEM) initiated with a Buy at Drexel Hamilton... Transocean (RIG) initiated with a Sell at Citi... Viacom (VIAB) initiated with a Buy at Pivotal Research... bluebird bio (BLUE) initiated with an Outperform at Oppenheimer.
ABEO Abeona Therapeutics
$6.86

0.07 (1.03%)

09/07/16
CANT
09/07/16
INITIATION
Target $21
CANT
Buy
Abeona Therapeutics initiated with a Buy at Cantor
Cantor initiated Abeona Therapeutics with a Buy and $21 price target.
09/21/16
MAXM
09/21/16
NO CHANGE
Target $8
MAXM
Buy
Abeona Therapeutics price target raised to $8 from $6 at Maxim
Maxim raised Buy rated Abeona's price target to $8 from $6 following news the company has licensed a next-generation AAV gene therapy platform from the University of North Carolina that may make gene therapy available to patients with CNS disorders who have immune responses against natural AAV vectors used in first-generation AAV gene therapies currently in development.
09/29/16
MAXM
09/29/16
NO CHANGE
Target $14
MAXM
Buy
Abeona Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised Abeona's price target to $14 from $8 saying he expects multiple data points across several gene therapy programs to potentially push shares higher. The analyst said clinical development is underway in Abeona's Sanfilippo with positive data in two patients so far, and data from more patients are expected this fall. The company is also advancing a second Sanfilippo gene therapy, ABO-101, into the clinic later this year. Also, Abeona has brought on board a more advanced gene therapy from Stanford University, EB-101, to treat a rare skin disease which demonstrated positive data in five patients and has advanced to phase II, McCarthy wrote.
12/16/15
12/16/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abeona Therapeutics (ABEO) initiated with a Buy at Maxim... Accelerate Diagnostics (AXDX) initiated with an Overweight at Piper Jaffray... Aetna (AET) initiated with a Neutral at Credit Suisse... Agenus (AGEN) initiated with a Buy at Jefferies... Apple Hospitality REIT (APLE) initiated with a Buy at Canaccord... Brunswick (BC) initiated with an Overweight at JPMorgan... Carlisle (CSL) initiated with a Buy at Wunderlich... Castlight Health (CSLT) initiated with a Buy at Topeka... Centene (CNC) initiated with an Outperform at Credit Suisse... ConAgra (CAG) initiated with a Buy at Jefferies... Dean Foods (DF) initiated with a Buy at Jefferies... First Merchants (FRME) initiated with a Neutral at SunTrust... Flowers Foods (FLO) initiated with a Buy at Jefferies... Glatfelter (GLT) initiated with a Buy at Sidoti... HCA Holdings (HCA) initiated with an Outperform at Credit Suisse... Hain Celestial (HAIN) assumed with a Buy at Jefferies... Hormel Foods (HRL) initiated with a Buy at Jefferies... Humana (HUM) initiated with a Neutral at Credit Suisse... Ingredion (INGR) initiated with a Buy at Jefferies... J & J Snack Foods (JJSF) initiated with a Hold at Jefferies... J.M. Smucker (SJM) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with a Buy at Citi... LifePoint (LPNT) initiated with an Outperform at Credit Suisse... MasterCard (MA) initiated with a Buy at UBS... Matador (MTDR) initiated with a Neutral at BofA/Merrill... McCormick (MKC) initiated with a Hold at Jefferies... Molina Healthcare (MOH) initiated with a Neutral at Credit Suisse... NetApp (NTAP) initiated with an Underperform at JMP Securities... Nimble Storage (NMBL) initiated with a Market Perform at JMP Securities... Pilgrim's Pride (PPC) initiated with a Hold at Jefferies... Pure Storage (PSTG) initiated with an Outperform at JMP Securities... Rexford Industrial (REXR) initiated with a Buy at Stifel... Rice Energy (RICE) initiated with a Hold at Deutsche Bank... Sanderson Farms (SAFM) initiated with an Underperform at Jefferies... Snyder's-Lance (LNCE) initiated with a Buy at Jefferies... SodaStream (SODA) initiated with a Hold at Jefferies... Tenet (THC) initiated with a Neutral at Credit Suisse... TreeHouse (THS) initiated with a Buy at Jefferies... Tyson Foods (TSN) initiated with a Buy at Jefferies... UnitedHealth (UNH) initiated with an Outperform at Credit Suisse... Universal Health (UHS) initiated with a Neutral at Credit Suisse... Varonis (VRNS) initiated with a Buy at Lake Street... Visa (V) initiated with a Buy at UBS... WellCare (WCG) initiated with an Underperform at Credit Suisse... WhiteWave (WWAV) initiated with a Buy at Jefferies... aTyr Pharma (LIFE) initiated with a Neutral at Citi.
ONCE Spark Therapeutics
$63.18

1.84 (3.00%)

09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
09/02/16
STFL
09/02/16
INITIATION
STFL
Buy
Spark Therapeutics initiated with a Buy at Stifel
Target $73.

TODAY'S FREE FLY STORIES

PKE

Park Electrochemical

$18.66

0.02 (0.11%)

06:31
06/28/17
06/28
06:31
06/28/17
06:31
Earnings
Park Electrochemical reports Q1 EPS before items 12c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$20.02

5.62 (39.03%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Recommendations
CB&I analyst commentary  »

Court ruling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

, TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Periodicals
Toshiba to file $1B lawsuit against Western Digital, Reuters reports »

Toshiba (TOSBF, TOSYY)…

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

WDC

Western Digital

$91.85

-0.81 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOP

Koppers Holdings

$34.00

-0.7 (-2.02%)

06:22
06/28/17
06/28
06:22
06/28/17
06:22
Upgrade
Koppers Holdings rating change  »

Koppers Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRB

H&R Block

$31.34

0.02 (0.06%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
H&R Block management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

, SYMC

Symantec

$28.11

-0.75 (-2.60%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Recommendations
Proofpoint, Symantec analyst commentary  »

Piper highlights…

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

SYMC

Symantec

$28.11

-0.75 (-2.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$34.48

0.1 (0.29%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
Houlihan Lokey management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HAL

Halliburton

$41.53

-0.17 (-0.41%)

06:17
06/28/17
06/28
06:17
06/28/17
06:17
Conference/Events
Halliburton management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 24

    Jul

FIVE

Five Below

$47.79

-0.545 (-1.13%)

06:16
06/28/17
06/28
06:16
06/28/17
06:16
Conference/Events
Five Below management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

AABA

Altaba

$53.64

-0.67 (-1.23%)

, BABA

Alibaba

$141.53

-1.2 (-0.84%)

06:15
06/28/17
06/28
06:15
06/28/17
06:15
Initiation
Altaba, Alibaba, Yahoo Japan initiated  »

Altaba initiated with an…

AABA

Altaba

$53.64

-0.67 (-1.23%)

BABA

Alibaba

$141.53

-1.2 (-0.84%)

YAHOY

Yahoo Japan

$8.77

0.05 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GIL

Gildan Activewear

$31.44

-0.3 (-0.95%)

06:08
06/28/17
06/28
06:08
06/28/17
06:08
Upgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:07
06/28/17
06/28
06:07
06/28/17
06:07
Syndicate
Government Properties files to sell 25M shares of common stock »

The joint bookrunning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRNT

Ceragon Networks

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Hot Stocks
Ceragon Networks receives new orders from Tier 1 South Cone operator »

Ceragon Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

FDC

First Data

$18.53

-0.18 (-0.96%)

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Downgrade
First Data rating change  »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGOV

NIC Inc.

$19.00

-0.55 (-2.81%)

06:05
06/28/17
06/28
06:05
06/28/17
06:05
Initiation
NIC Inc. initiated  »

NIC Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:02
06/28/17
06/28
06:02
06/28/17
06:02
Hot Stocks
First Potomac to be acquired by Government Properties in $1.4B deal »

First Potomac Realty…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:01
06/28/17
06/28
06:01
06/28/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Hot Stocks
Breaking Hot Stocks news story on First Potomac, Government Properties »

First Potomac to be…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$21.13

-0.18 (-0.84%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Syndicate
Canada Goose 12.5M share Secondary priced at $20.75 »

CIBC, Credit Suisse,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RGEN

Repligen

$43.25

-2.09 (-4.61%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Syndicate
Repligen 2.807M share Spot Secondary priced at $42.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GDX

Market Vector Gold Miners

$22.26

-0.3 (-1.33%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.81

0.45 (0.38%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.50

-1.23 (-3.76%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYG

Tortoise Energy

$29.13

-0.14 (-0.48%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Upgrade
Tortoise Energy rating change  »

Tortoise Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.89

-0.46 (-2.38%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.